Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after N
Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. The study seeks to determine the efficacy and safety of sunitinib in patients with locoregional renal-cell carcinoma at high risk for tumor recurrence after nephrectomy.

http://www.nejm.org/doi/full/10.1056/NEJMoa1611406
Like
Comment
Share